Back to Journals » Cancer Management and Research » Volume 7

Treatment of metastatic colorectal cancer: focus on panitumumab

Authors Tay R, Wong R, Hawkes E

Received 6 April 2015

Accepted for publication 5 May 2015

Published 24 June 2015 Volume 2015:7 Pages 189—198

DOI https://doi.org/10.2147/CMAR.S71821

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Kenan Onel


Rebecca Y Tay,1 Rachel Wong,1–3 Eliza A Hawkes1,3,4

1Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia; 2Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; 3Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia; 4Department of Oncology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Heidelberg, VIC, Australia

Abstract: Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

Keywords: panitumumab, metastatic colorectal cancer, KRAS, RAS, EGFR, monoclonal antibody

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]